Open $40.21
Day Range 39.91 - 40.60
52 Week Range 29.94 - 43.08
Market Cap $223.63B
Shares Outstanding 5.6B
Public Float 5.6B
Beta 0.68
Rev. per Employee $533.86K
P/E Ratio 20.33
EPS $1.97
Yield 3.90%
Dividend $0.39
Ex-Dividend Date May 6, 2021
Short Interest 58.02M 04/30/21
% of Float Shorted 1.04%
Average Volume 29.32M

5 Day	-0.40%
1 Month	3.28%
3 Month	16.61%
YTD	8.53%
1 Year	12.46%

Sell
Under
Hold
Over
Buy

Number of Ratings 20 Full Ratings

MarketWatch
Dow Jones

Pfizer is testing a COVID-19 booster shot in combination with new pneumococcal conjugate vaccine candidate

May. 24, 2021 at 7:35 a.m. ET by Jaimy Lee

Pfizer says new study aims to review safety when both vaccines are co-administered in adults age 65 or older

May. 24, 2021 at 6:54 a.m. ET by Ciara Linnane

Pfizer starts study of 20-valent pneumococcal conjugate vaccine candidate with 3rd dose of COVID vaccine

May. 24, 2021 at 6:54 a.m. ET by Ciara Linnane

Pfizer Studying Coadministration of Covid-19 Booster, Pneumococcal Shots

May. 24, 2021 at 6:53 a.m. ET

With Olympics approaching, Japan speeds up vaccination rollout

May. 23, 2021 at 11:29 p.m. ET by Associated Press

COVID-19 vaccines effective against Indian variant, U.K. health officials say

May. 23, 2021 at 4:25 p.m. ET by Associated Press

Pfizer Inc. stock falls Friday, underperforms market

May. 21, 2021 at 5:16 p.m. ET by MarketWatch Automation

Booster dose of COVID vaccines to be given to U.K. volunteers in new trial

May. 21, 2021 at 3:56 p.m. ET by Lina Saigol

Barron's

BioNTech Says Covid-19 Vaccine Likely to Be Effective Against Indian Coronavirus Variant

May. 21, 2021 at 7:22 a.m. ET by Barron's

Barron's

Merck Battles Pfizer in Lucrative Pediatric Vaccine Market

May. 21, 2021 at 10:49 a.m. ET by Barron's

BioNTech says COVID-19 vaccine likely to be effective against Indian coronavirus variant

May. 21, 2021 at 6:24 a.m. ET by Steve Goldstein

Barron's

U.S. Treasury Proposes Global Minimum Corporate Tax of At Least 15%

May. 20, 2021 at 11:17 a.m. ET

Pfizer Inc. stock rises Thursday, still underperforms market

May. 20, 2021 at 5:16 p.m. ET by MarketWatch Automation

WHO Europe advises avoiding international travel for now as concern about vaccine inequity grows

May. 20, 2021 at 10:51 a.m. ET by Ciara Linnane

Barron's

5 Biopharma Stocks That Are Cheap and Growing

May. 20, 2021 at 7:00 a.m. ET by Barron's

Pfizer, BioNTech Boost Supply Agreement With Turkey

May. 20, 2021 at 6:21 a.m. ET

UPDATE: Pfizer and BioNTech to supply EU with up to 1.8 billion additional COVID vaccine doses

May. 20, 2021 at 6:09 a.m. ET by Ciara Linnane

Pfizer and BioNTech to supply EU with up to 1.8 bln additional COVID vaccine doses

May. 20, 2021 at 5:59 a.m. ET by Ciara Linnane

Pfizer Inc. stock underperforms Wednesday when compared to competitors

May. 19, 2021 at 5:16 p.m. ET by MarketWatch Automation

10 countries where vaccinated Americans are allowed to travel — but it won’t come cheap

Apr. 7, 2021 at 2:35 p.m. ET by Jacob Passy

No Headlines Available

Other News
Press Releases

Royal Caribbean May Require Vaccination for Passengers as Young as 12

May. 24, 2021 at 7:00 a.m. ET on Motley Fool

The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck

May. 24, 2021 at 6:49 a.m. ET on Zacks.com

3 Reasons Why This Vaccine Maker May Dominate the European Market

May. 24, 2021 at 6:00 a.m. ET on Motley Fool

5 Stocks Billionaires Couldn't Stop Buying in Q1

May. 24, 2021 at 5:51 a.m. ET on Motley Fool

Goldman Sachs Remains a Hold on Pfizer (PFE)

May. 24, 2021 at 2:55 a.m. ET on SmarterAnalyst

J.P. Morgan Remains a Hold on Pfizer (PFE)

May. 24, 2021 at 2:55 a.m. ET on SmarterAnalyst

Is Pfizer Stock Still a Top Buy for 2021?

May. 23, 2021 at 5:11 a.m. ET on Motley Fool

The Best News and Worst News from BioNTech's Q1 Results

May. 22, 2021 at 10:01 a.m. ET on Motley Fool

Is BioNTech a Buy?

May. 22, 2021 at 6:40 a.m. ET on Motley Fool

Pfizer's COVID Vaccine Authorized for Adolescents: Here's Why It's Not a Big Deal For Now

May. 22, 2021 at 6:02 a.m. ET on Motley Fool

Pfizer/BioNTech to Supply 1.8B More Doses of Comirnaty in EU

May. 21, 2021 at 11:50 a.m. ET on Zacks.com

Merck's (MRK) Pneumococcal Vaccine Succeeds in Pediatric Trials

May. 21, 2021 at 10:01 a.m. ET on Zacks.com

Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal

May. 21, 2021 at 9:51 a.m. ET on Zacks.com

Inovio's Latest COVID Vaccine Results: Too Little, Too Late?

May. 21, 2021 at 7:10 a.m. ET on Motley Fool

2 Blue Chips I'd Love to Buy in a Bear Market

May. 21, 2021 at 6:10 a.m. ET on Motley Fool

Why Moderna Shot 5%-Plus Higher on Thursday

May. 20, 2021 at 5:26 p.m. ET on Motley Fool

Moderna Holds the Key to the Future of mRNA Vaccines

May. 20, 2021 at 2:16 p.m. ET on InvestorPlace.com

3 Vanguard ETFs for Opportunistic Investors to Buy Right Now

May. 20, 2021 at 6:42 a.m. ET on Motley Fool

2 Things That May Boost This Beaten-Down Vaccine Stock

May. 20, 2021 at 6:00 a.m. ET on Motley Fool

Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data

May. 19, 2021 at 8:37 a.m. ET on Zacks.com

No Headlines Available

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Name	Chg %	Market Cap
Eli Lilly & Co.	0.18%	$191.69B
AstraZeneca PLC ADR	-0.07%	$151.23B
Johnson & Johnson	-0.06%	$450.21B
Bristol Myers Squibb Co.	0.07%	$149.78B
Novartis AG ADR	0.19%	$199.24B
Abbott Laboratories	-0.57%	$208.12B
Amgen Inc.	-0.37%	$144.22B
GlaxoSmithKline PLC ADR	-0.46%	$95.84B
Merck & Co. Inc.	-0.60%	$200.49B

Competitor Data Provided By